CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
供者来源 CD19 CAR-T 二次治疗对首次自体 CAR-T 治疗后髓外复发的急性淋巴细胞白血病安全有效
英文原题：Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy.
查看英文原题
Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管治疗手段不断进步，复发/难治性（R/R）B系急性淋巴细胞白血病（B-ALL）成人患者的预后仍然很差，预期五年总生存期（OS）率为10% 20%（Nguyen et al., 2008; Oriol et al., 2010）。B-ALL的髓外复发被视为高危因素，通常与较差的生存相关，约占所有复发患者的15%至20%（Ding et al., 2017; Sun et al., 2018）。中枢神经系统（CNS）和睾丸是B-ALL髓外复发最常见的部位。此外，髓外白血病还可出现在皮肤、眼睛、乳房、骨骼、肌肉和腹部器官。异基因造血干细胞移植（allo-HSCT）后复发的髓外B-ALL预后极差（Spyridonidis et al., 2012; Dahlberg et al., 2019）。常规化疗或放疗对此类患者往往无效。目前，对于allo-HSCT后髓外白血病的治疗尚无最佳治疗策略。
展开英文摘要原文
Despite the advancement of treatments, adults with relapsed/refractory (R/R) B-lineage acute lymphoblastic leukemia (B-ALL) have poor prognosis, with an expected five-year overall survival (OS) rate of 10% 20% (Nguyen et al. , 2008; Oriol et al. , 2010).
Extramedullary relapse of B-ALL is regarded as a high-risk factor generally associated with poor survival, occurring in about 15% to 20% of all relapsed patients (Ding et al. , 2017; Sun et al. , 2018). The central nervous system (CNS) and the testes are the most common sites of extramedullary relapse of B-ALL.
In addition, extramedullary leukemia can appear in the skin, eyes, breasts, bones, muscles, and abdominal organs. The prognosis of relapsed extramedullary B-ALL after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is extremely poor (Spyridonidis et al. , 2012; Dahlberg et al. , 2019). Conventional chemotherapy or radiation is often ineffective in such patients. At present, there are no optimal treatment strategies for treating extramedullary leukemia after allo-HSCT.
论文信息
- 作者
- Kong D、Yang T、Geng J、Jing R、Zhang Q、Wei G、Huang H、Hu Y
- 第一作者单位
- Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.China
- 通讯作者单位
- Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. 1313016@zju.edu.cn.China
- 期刊
- Journal of Zhejiang University. Science. B2022 Oct 15
- 原文标识
- PubMed 36226540 · DOI 10.1631/jzus.B2200128
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →